Pathologist Asks: Where Are Investigations Into Organ Damage Caused by COVID Vaccine?

This information was not discussed in the media and not considered by the FDA, and it continues to be buried as government agencies push for 100% vaccination in the U.S.

In the study, the researchers created a pseudo-virus12 that contained the spike protein but did not contain the virus. Using an animal model, they showed that the virus was not necessary to create damage and inflammation.

When the S protein attached to the ACE2 receptor it disrupted signaling to the mitochondria and caused damage and fragmentation. The alterations in mitochondrial function were confirmed as part of the inhibition of ACE2 signaling in the lab.

The results also revealed that the virus could induce endothelial cell inflammation and endotheliitis. The protein reportedly decreased ACE2 levels and impaired nitric oxide bioavailability. Co-senior scientist of the study, Uri Manor, explained in a press release from Salk Institute:

“If you remove the replicating capabilities of the virus, it still has a major damaging effect on the vascular cells, simply by virtue of its ability to bind to this ACE2 receptor, the S protein receptor, now famous thanks to COVID. Further studies with mutant spike proteins will also provide new insight towards the infectivity and severity of mutant SARS CoV-2 viruses.”

Further study demonstrates the effect of the spike protein

Then, a second paper published online March 8, investigated the potential that the spike protein is an inflammagen, or an irritant that can trigger inflammation at the cellular level. The researchers sought to determine if the spike protein was the underlying cause of the hypercoagulation found with a COVID-19 infection.

Mass spectrometry showed the spike protein damaged fibrinogen, prothrombin and complement 3, all compounds used in coagulation. They suggested that the presence of the protein was contributing to hypercoagulation and may result in large microclots that have been observed in plasma samples from patients infected with COVID-19.

Again, science demonstrated that it wasn’t the virus causing endothelial damage that led to organ damage, such as was found in the heart, liver and kidney of COVID-19 patients. Rather, it was the spike protein that was also being injected in a genetic therapy shot program.

A third study published April 27 again demonstrated in an animal model that exposure to the spike protein alone was enough to induce severe lung damage. And yet, there was no move by governmental agencies to slow the distribution of this genetic experiment.

Researchers have continued to study how the spike protein affects the endothelial cells, and ultimately damages the heart muscle. A study published in June in Frontiers in Cardiovascular Medicine demonstrated that the spike protein down regulates the expression of junctional proteins found in the arteries. They concluded:

“… these experiments reveal that Spike-induced degradation of endothelial junctional proteins affects endothelial barrier function and is the likely cause of vascular damage observed in COVID-19 affected individuals.”

Even as researchers identify the pathway the spike protein takes to damage the endothelial cells, it is patently ignored by the mainstream media, governmental agencies and many health experts who continue to push the public into vaccinating with a genetic therapy injection that does not effectively keep you from getting the disease or stop you from spreading the disease.

Infection starts and may stay in the lungs

Interestingly, another study published in March 2021 questioned if the prevalence of inflammatory heart disease after COVID-19 infection in professional athletes would affect their ability to return to play.

The researchers evaluated 789 professional athletes who had COVID-19 and found no adverse cardiac events in those who underwent cardiac screening. In this group of healthy individuals, it appeared very rare for there to be systemic involvement of the spike protein.

However, in the VAERS reports Sept. 3, there were a total of 11,793 individuals who suffered heart attack, myocarditis or pericarditis in the nine months that the vaccine had been administered. The effect of COVID-19 on the heart is well documented.

In my interview with Dr. Vladimir Zelenko in February, we discussed the treatment of COVID-19 with hydroxychloroquine. At that point, Zelenko had treated 3,000 patients with symptoms of COVID-19 and only three of his high-risk patients had subsequently succumbed to the disease.

While the focus of the interview was on treatment protocols and the use of the antimalarial drug hydroxychloroquine, Zelenko shared an interesting statistic about his protocol.

In the early months of COVID-19, Zelenko decided to treat his high-risk patients as early as possible, without waiting for severe symptoms. This turned out to be one key to his significant success.

His understanding of the mechanism behind hydroxychloroquine and zinc led to using the combination alongside azithromycin, to prevent bacterial pneumonia and other bacterial infections common with COVID.

What is interesting are the statistics for Zelenko’s patients with long haul symptoms. Data from the University of Washington in 2021 found 32.7% of outpatients with COVID-19 go on to experience persistent symptoms.

However, Zelenko had treated 3,000 patients and none who received treatment within the first five days went on to develop long-haul symptoms. His data was from the same period as that of the University of Washington.

While he has had patients with persistent symptoms from COVID-19, they sought medical care after the first five days of symptoms, which meant the inflammatory process had advanced. From his experience, and the experience of the patients he treated, early intervention with the protocol nearly eliminated the risk of persistent symptoms.